Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865852 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00865852 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants.
The verdict
NCT00865852, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 750 mg) in healthy adult volunteers under non-fasting conditions
Interventions
- DRUG Metformin HCl 750 mg Extender Release tablets, single dose
- DRUG GLUCOPHAGE® XR 750 mg tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-08 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865852
The ClinicalTrials.gov registry entry for NCT00865852 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin HCl 750 mg Extender Release tablets, single dose is the first listed.
NCT00865852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865852 about?
NCT00865852 is a clinical study titled "A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions". The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 750 mg) in healthy adult volunteers u...
What is the current status of trial NCT00865852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-08. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00865852?
The interventions under investigation include: Metformin HCl 750 mg Extender Release tablets, single dose (DRUG), GLUCOPHAGE® XR 750 mg tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00865852?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.